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o develop an inducible and progressive model of
mammary gland tumorigenesis, transgenic mice were
generated with a mouse mammary tumor virus–long
terminal repeat–driven, conditional, ﬁbroblast growth factor
(FGF)–independent FGF receptor (FGFR)1 (iFGFR1) that
 
can be induced to dimerize with the drug AP20187. Treatment
of transgenic mice with AP20187 resulted in iFGFR1 tyrosine
phosphorylation, increased proliferation, activation of
mitogen-activated protein kinase and Akt, and lateral
budding. Lateral buds appeared as early as 3 d after
T
 
AP20187 treatment and initially consisted of bilayered
epithelial cells and displayed apical and basolateral polarity
appeared after 13 d of AP20187 treatment. Invasive lesions
characterized by multicell-layered lateral buds, decreased
myoepithelium, increased vascular branching, and loss of
cell polarity were observed after 2–4 wk of treatment.
These data indicate that acute iFGFR1 signaling results in
increased lateral budding of the mammary ductal epithelium,
and that sustained activation induces alveolar hyperplasia
and invasive lesions.
 
Introduction
 
The fibroblast growth factor (FGF)* family consists of 
 
 
 
20
ligands and four receptor tyrosine kinase genes that have
been shown to be important regulators of angiogenesis and
embryonic organogenesis (Ornitz, 2000). Loss-of-function
experiments have demonstrated that FGFs are critical factors
for limb bud outgrowth, lung development, gastrulation, and
brain development (Lewandoski et al., 2000). In the adult,
aberrant regulation of FGF ligands and their receptors is
associated with breast and prostate tumorigenesis (Giri et al.,
1999; Valve et al., 2001). Therefore, understanding the func-
tion of FGFs and FGF receptors (FGFRs) will be a crucial
step in elucidating mechanisms of cellular transformation.
The expression of FGF ligands and FGFRs is develop-
mentally regulated in the mammary gland (Coleman-
Krnacik and Rosen, 1994; Chodosh et al., 2000), where
they are generally expressed during ductal morphogenesis
and decrease throughout pregnancy and lactation. Ductal
morphogenesis is a highly proliferative stage during mam-
mary gland development, during which the gland invades the
stromal fat pad and establishes a branched ductal network
(Williams and Daniel, 1983). FGFR1 is mainly expressed
during this stage of development (Chodosh et al., 2000).
Additionally, expression of a dominant negative FGFR2 in
the mammary gland during pregnancy has been shown to
inhibit lobuloalveolar development (Jackson et al., 1997).
This expression profile suggests that FGF signaling plays an
important role in normal mammary gland development.
The observation that mouse mammary tumor virus
(MMTV) proviral insertion can activate FGF-3, FGF-4, and
FGF-8 and leads to mammary tumorigenesis has revealed
that FGF ligands are potent mammary gland mitogens (van
Leeuwen and Nusse, 1995). The direct transforming activity
of the same FGFs in the mammary gland was subsequently
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confirmed using transgenic mouse models (Daphna-Iken et
al., 1998). Additionally, inappropriate regulation of FGFs
and their receptors has been observed in breast cancer cell
lines and in 
 
 
 
10–20% of primary breast tumors (Penault-
Llorca et al., 1995; Marsh et al., 1999). These data suggest
that aberrant FGF signaling may exert potent transforming
capacity in the mammary gland.
In the present study, the effects of FGFR1 signaling have
been investigated using a novel, inducible FGFR oligomer-
ization and activation system. This system was first charac-
terized in fibroblasts and mammary epithelial cells, and then
in a transgenic mouse model. Inducible iFGFR1 signaling in
mammary epithelium resulted in progressively invasive le-
sions occurring rapidly within 2–4 wk after iFGFR1 activa-
tion. iFGFR1 kinase-induced lesions were examined for cell
polarity, hormonal dependence, and invasive properties.
This work describes the first application of an inducible
dimerization system for studying receptor tyrosine kinase
signaling in a transgenic mouse model.
 
Results
 
Generation of an inducible iFGFR1 construct
 
A ligand-independent activation system of the FGFR was
employed to study the progressive steps of mammary gland
transformation. This system is based on the ability of the
FK506 binding protein-12 (FKBP12) to interact with its
naturally occurring ligand, FK506 (Spencer et al., 1993;
Pruschy et al., 1994). The interaction of FKBP12 with
FK506 occurs at a stochiometry of 1:1; thus, the tethering
of two FK506 compounds results in a bivalent drug
(FK1012) with the capacity to interact with and dimerize
two FKBP12 containing proteins. This system has been
used to study dimerization-induced signaling by several cell
surface receptors, including members of the ErbB family of
receptor tyrosine kinases and the T-cell receptor, as well as
by intracellular proteins such as caspases (Spencer et al.,
1993; Fan et al., 1999; Muthuswamy et al., 1999, 2001).
Using this strategy, chimeric proteins that contain the
FGFR kinase domain fused to FKBP12 can be induced to
dimerize in the presence of FK1012. A synthetic analogue
of FK1012 used in the present studies, AP20187, has been
modified to reduce interactions with endogenous FKBPs,
and specifically interacts with a variant of FKBP12 contain-
ing an F36V mutation (Clackson et al., 1998; Yang et al.,
2000). The FGFR–FKBPv fusion proteins (iFGFRs) gener-
ated in this study lack the extracellular ligand binding and
transmembrane domains, contain an NH
 
2
 
-terminal myri-
stylation sequence, an intracellular FGFR kinase domain,
two FKBPv domains, and a COOH-terminal hemaggluti-
nin (HA) epitope sequence (Fig. 1 A). The FGFR1 kinase
domain used to generate the iFGFR1 construct contains the
intracellular domain of FGFR1 (amino acids 365–822,
EMBL/GenBank/DDBJ accession no. U22324) starting
three amino acids from the end of the transmembrane do-
main. Although all four FGFRs were subcloned with the
FKBPv domains, only the results obtained with iFGFR1
will be described in detail. A control FKBPv construct also
was designed that contains all of the above domains except
the FGFR sequences.
 
AP20187-dependent activation of iFGFR1 signaling in 
NIH3T3 fibroblasts and HC11 mammary epithelial cells
 
The phosphorylation levels of iFGFR1, mitogen-activated
protein kinase (MAPK), and Akt were determined in both
NIH3T3 and HC11 cells transduced with retroviral expres-
sion constructs to examine the downstream effects of
iFGFR1 dimerization (Fig. 1, A and B). An increase in the
tyrosine phosphorylation of iFGFR1 was rapidly detected
after AP20187 treatment of iFGFR1-transduced NIH3T3
cells, as determined by immunoprecipitation and immuno-
blotting using phosphotyrosine and HA epitope antibodies,
respectively (Fig. 1 B). Phosphorylation of both MAPK and
Akt was also detected in AP20187-treated NIH3T3 fibro-
blasts and HC11 mammary epithelial cells (Fig. 1 C). Simi-
lar results were obtained with placement of the FKPBv
domain NH
 
2
 
-terminal to the FGFR1 kinase domain (un-
published data). No increase in MAPK or Akt phosphor-
ylation was observed with cells transduced with FKBPv
alone and treated with AP20187 (unpublished data). FGF
signaling has been shown to specifically induce tyrosine
phosphorylation of the 90-kD adapter protein FRS2/SNT.
The tyrosine phosphorylation of FRS2/SNT was examined
in AP20187-treated iFGFR1-transduced NIH3T3 fibro-
blasts to determine if iFGFR1 activation can signal through
this pathway. FRS2/SNT was observed to be highly tyrosine
phosphorylated in response to AP20187 treatment (Fig. 1
D), demonstrating that iFGFR1 signaling can activate phys-
iological FGF signaling pathways.
The iFGFR1 and FKBPv constructs were tested in both the
fibroblast and mammary epithelial cell lines to determine if
they could functionally recapitulate effects mediated by FGF
signaling in an AP20187-dependent fashion. One characteris-
tic of NIH3T3 fibroblasts is their dependence on serum
growth factors for survival and proliferation. iFGFR1 and
FKPBv stably transfected NIH3T3 cells were plated in dupli-
cate plates, grown to subconfluence, placed in serum-free me-
dia containing either 30 pM AP20187 or vehicle alone, and
then observed for morphological changes over a 72-h time
course. When grown in serum-free media in the absence of
AP20187, iFGFR1 cells displayed distinct morphological fea-
tures associated with apoptosis, including membrane blebbing,
rounding, and detachment from the surface of the cell culture
dish (Fig. 1 E, iFGFR1
 
 
 
; unpublished data). Similar results
were obtained with the pBK-neo and FKBPv stably transfected
cells in serum-free media treated with and without AP20187
(Fig. 1 E, pBKneo
 
 
 
, pBKneo
 
 
 
;
 
 
 
unpublished data). However,
iFGFR1 cells treated with AP20187 in the absence of serum re-
mained attached to the cell culture dish, formed distinct multi-
cellular foci and did not display morphological features charac-
teristic of apoptosis (Fig. 1 E, iFGFR1
 
 
 
). A twofold increase
in the number of viable cells was observed 48 h after treatment
with AP20187 as determined by bioreduction of MTS (Fig. 1
E, iFGFR
 
 
 
). These changes were similar to those observed af-
ter treatment of NIH3T3 cells with recombinant FGF-8 under
the same serum-free conditions (Fig. 1 F, rFGF8). Thus, treat-
ment of cells stably transfected with iFGFR1 with AP20187 in-
duced a survival response and prevented the contact inhibition
that is normally observed in NIH3T3 cells.
Caspase-3 activation was assayed in serum-starved,
iFGFR1-transduced NIH3T3 cells in the presence or ab- 
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Figure 1. iFGFR1 dimerization can inhibit apoptosis and induce 
proliferation. (A) Schematic drawing of FGF-induced dimerization 
of FGFR and conditional dimerization of the iFGFR1 fusion protein 
by AP20187. (B) iFGFR1 is phosphorylated in response to AP20187 
treatment. Phosphorylated proteins were immunoprecipitated 
using anti–phospho-tyrosine antibodies and examined by Western 
analysis with anti-HA epitope antibodies. (C) Western blot of protein 
extracts isolated from serum-starved NIH3T3 and HC11 cells 
treated with AP20187 at several time points after treatment 
(in minutes). Anti–phospho-MAPK and -Akt antibodies show activation 
of these kinases in response to AP20187 treatment. (D) FRS2/SNT was immunoprecipitated using anti-FRS2 antibodies and tyrosine 
phosphorylation was analyzed by immunoblotting with anti–phospho-tyrosine antibodies (top). Equal loading of protein on the blot was 
determined by reprobing the membrane with anti-FRS2 antibodies (bottom). (E) Survival assays were performed using serum-starved 
NIH3T3 cells. iFGFR1 cells were stably transfected with iFGFR1, whereas pBKneo cells were stably transfected with pBKneo neomycin 
selection cassette. iFGFR1  and pBKneo  cells were treated with 30 pM AP20187, whereas iFGFR1  and pBKneo  cells were treated 
with ethanol solvent. iFGFR1  cells remained viable when serum starved. (F) The change in cell number from survival assays was quantitated 
by MTS bioreduction. The fold-change in cell number was determined by normalizing to the untreated control ( AP20187 or without 
rFGF8) for each condition. (G) Caspase-3 fluorometric peptide cleavage assay of serum-starved NIH3T3 cells transduced with iFGFR1 
or FKBPv alone and treated with increasing concentrations of AP20187. AP20187-treated iFGFR1 cells showed reduced caspase-3 activity 
when compared with FKBPv control cells. Data points represent quadruplicate wells. (H) Fold difference in proliferation of AP20187-treated 
serum-starved NIH3T3 and HC11 cells. Spotted bars represent iFGFR1 and solid black bars FKBPv controls. Data were normalized to cells 
treated with solvent. Proliferating cells were determined by  2 N DNA content as measured by propidium iodide staining and FACS analysis. 
Only iFGFR1-transduced HC11 cells showed an increase in proliferation in response to AP20187. Data points represent at least three 
independent analyses. Error bars represent standard error of the mean. Bars, 5  m. 
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treatment, the inguinal mammary glands were biopsied
for whole-mount and immunofluorescence analyses (Fig.
2). Whole-mount analysis of the mammary epithelium
showed no gross morphological differences between age-
matched nontransgenic littermates treated with AP20187
and transgenic littermates treated with solvent only (Fig. 2,
A–D). However, transgenic mice treated with AP20187
displayed increased lateral budding along the ductal epithe-
lium (Fig. 2, E and F). AP20187-induced lateral budding
was observed throughout the mammary gland and appeared
on primary, secondary, and tertiary ductal branches. In-
creased lateral budding was also observed at the distal tips
of the mammary epithelium (Fig. 2, E and F, arrowhead).
Additionally, regional increases in ductal branching were
observed in AP20187 treated transgenic mice (Fig. 2, E
and F, arrows). Histological analysis revealed extensive lat-
eral buds, with single and multicell-layered epithelium lin-
ing the ducts (Fig. 2 L). Although these lateral buds did
contain lumens, many of these appeared constricted or
convoluted.
 
AP20187-induced lateral budding does not require 
ovarian hormones
 
Transgenic mice were ovariectomized (ovex), and 2 d later
were treated with AP20187 every 3 d for 16 d to determine
if ovarian hormonal regulation is required for the lateral
budding phenotype. Whole-mount analysis of ovex non-
transgenic littermates treated with AP20187 showed con-
striction of ductal epithelium and a loss of terminal-end
buds (TEBs), consistent with the loss of the inductive ef-
fects from the steroid hormones estrogen and progesterone
(Fig. 2, G and H). However, when ovex transgenic mice
were treated with AP20187, dilated ductal epithelium and
large bloated structures at the distal tips of the ductal net-
work were observed (Fig. 2, I and J, arrowheads). Regions
of increased ductal branch points were also observed in
ovex AP20187-treated transgenic mice (Fig. 2, I and J,
arrows). The ductal network did not completely fill the
fat pad in either transgenic or nontransgenic ovex mice
treated with AP20187, suggesting that iFGFR1 activation
cannot, by itself, rescue normal ductal elongation in the
absence of ovarian hormones. However, the observation
that iFGFR1-induced lateral budding occurred in the ovex
background demonstrates that ovarian hormones are not
required for this phenotype.
 
Transgene expression is localized to ductal 
and lateral bud epithelium
 
The localization of transgene expression in the mammary
gland of transgenic mice was determined by immunofluo-
rescent detection of the HA-epitope on the iFGFR1 pro-
tein. Mammary epithelial cells expressing the HA-epitope
were observed in transgenic mice, but not in nontransgenic
littermates (Fig. 2, M and N). Expression of the iFGFR1
protein was localized to the periphery of the cell and no
nuclear staining was apparent, consistent with membrane
targeting by the myristylation sequence. Transgene ex-
pression was punctate along the ductal epithelium of
untreated 8-wk-old transgenic mice (unpublished data),
 
sence of AP20187 to quantitate the iFGFR1-induced inhibi-
tion of apoptosis (Fig. 1 G). Cells were placed in serum-free
medium with or without AP20187 for 24 h. Under these
conditions, a significant dose-dependent decrease in caspase-3
activity was detected beginning with a dose of 0.5 pM
AP20187 (Fig. 1 G, solid line). A maximal decrease was
achieved with 30 pM AP20187. No significant decrease in
caspase-3 activity was detected using the control FKBPv
construct (Fig. 1 G, dashed line). An AP20187-dependent
increase in mRNA for the antiapoptotic factor Bcl-xl was
also observed (unpublished data). These data suggest that
iFGFR1 activation can inhibit caspase-3–mediated apopto-
sis caused by serum withdrawal.
Cell cycle analysis was employed in these two different cell
types to determine if the AP20187-induced iFGFR1 sig-
naling pathway also regulates proliferation. Transduced
NIH3T3 fibroblasts and HC11 mammary epithelial cells
were treated with AP20187 in serum-free media and cellular
DNA content was quantitated by propidium iodide staining
and FACS (Fig. 1 H). NIH3T3 cells expressing iFGFR1
showed no change in proliferation with or without
AP20187. However, HC11 cells expressing iFGFR1 showed
greater than a twofold increase in proliferation in response
to AP20187. In the presence or absence of AP20187, no dif-
ference in proliferation was detected in the control FKBPv
transduced HC11 or NIH3T3 cells (Fig. 1 H, black bars).
These data suggest that iFGFR1-regulated signaling path-
ways may exert functionally different effects that are cell
type dependent. Although iFGFR1 appears to activate the
same downstream pathways in fibroblasts and mammary ep-
ithelial cells, effects on their proliferation are not equivalent.
 
Generation of MMTV iFGFR1 transgenic mice
 
Transgenic mice were generated that express the iFGFR1
construct under the control of the MMTV long-terminal re-
peat (LTR). iFGFR1 and iFGFR2 constructs were sub-
cloned into an MMTV transgene cassette for the generation
of transgenic mice (Leder et al., 1986). Three iFGFR1 and
four FGFR2-FKBPv lines were generated that transmitted
the transgene through the germline. Of these seven lines,
three (one iFGFR1 and two iFGFR2) expressed the trans-
gene in the mammary gland as detected by Western blot
analysis of the HA epitope tag (unpublished data). All three
expressing lines displayed normal morphology in virgin mice
and similar inducible phenotypes described below. A de-
tailed characterization was performed on the iFGFR1 line
4775, which expressed low levels of iFGFR1 mRNA, detect-
able by RT-PCR, and low levels of protein expression as de-
termined by Western blot analysis (unpublished data).
 
Activation of iFGFR1 results in increased lateral buds
 
To analyze the ductal morphology of mammary glands in
the expressing transgenic lines, whole-mount analysis of
the thoracic and inguinal glands was performed. 6-wk-old
transgenic and control mice were treated intraperitoneally
with injections (50 
 
 
 
g at 0.5 mg ml
 
 
 
1
 
) of AP20187 every
3 d for 16 d, or by intrascapular implantation of Alzet
minipumps containing 100 
 
 
 
l of 0.5 mg ml
 
 
 
1
 
 AP20187
which delivered 0.25 
 
 
 
l h 
 
 
 
1
 
 for 2 wk. After AP20187 
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most likely due to an incomplete penetrance of the
MMTV LTR-driven transgene, whereas AP20187-induced
lateral buds were strongly immunoreactive (Fig. 2 N).
Thus, it is possible that AP20187 treatment results in the
expansion of transgene positive cells, as a result changing
the expression from a punctate to a multifocal pattern.
However, not all cells in lateral buds expressed the HA-
tagged transgene. Instead, lateral buds contained a mix-
ture of cell types including either transgene positive or
progesterone receptor (PR)-positive cells (unpublished
data). PR-positive cells within lateral buds and lining the
ducts were 5-bromo-2
 
 
 
-deoxyuridine (BrdU) negative, con-
sistent with the observed quiescent nature of PR-express-
ing cells in the mammary gland (unpublished data) (Sea-
groves et al., 2000).
 
Chronic activation of iFGFR1 results in progressively 
invasive lesions
 
Whole-mount, histological, and immunofluorescent analy-
ses were utilized to characterize the progressive nature of the
iFGFR1-induced lesions. To characterize these lesions mor-
phologically, whole mounts and paraffin-embedded sections
were stained with hematoxylin or hematoxylin and eosin
(H&E), respectively. In addition, cell polarity was deter-
mined by indirect immunofluorescence microscopy using
antibodies directed against specific, apical tight junction
(ZO-1) and basal, basement membrane (laminin) markers.
iFGFR1-induced lesions were classified into three morpho-
logically distinct types. Type I lateral buds were character-
ized by the presence of a single layer of cubodial epithelium
surrounded by myoepithelial cells, and with basally localized
Figure 2. iFGFR1 signaling can induce lateral buds in mammary 
glands of transgenic mice. Whole-mount and histological analyses 
of MMTV-iFGFR1 transgenic and wild-type littermates injected i.p. 
with AP20187 or diluent. Whole mounts of mammary glands at 4  
magnification (A, C, E, G, and I) and 10  magnification (B, D, F, H, 
and J). (A and B) Wild-type mouse treated with AP20187. (C and D) 
Transgenic mouse treated with diluent. (E and F) Transgenic mouse 
treated with AP20187. (G and H) Ovex wild-type mouse treated 
with AP20187. (I and J) Ovex transgenic mouse treated with 
AP20187. Arrows indicate regions of increased branching and 
arrowheads show lateral budding at distal regions of ducts. (K) H&E 
stain of transgenic mouse treated with diluent. (L) Transgenic 
mouse treated with AP20187. (M) Wild-type mouse stained with 
anti-HA antibody and Texas red secondary and DAPI-stained nuclei. 
(N) Transgenic mouse stained with anti-HA antibody and DAPI 
showing transgene localization in the lateral buds. Bars, 5  m. 
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laminin and apically localized ZO-1. Type-I lesions ap-
peared within 3 d of AP20187 treatment and were similar
to lateral alveolar buds induced in early pregnancy (Fig.
3 A, type I) (Daniel and Silberstein, 1987). However, un-
like lobuloalveolar development during late pregnancy, the
iFGFR1-induced lateral buds remained closely associated
with their primary ducts and did not completely occupy the
interductal stroma.
After 
 
 
 
2 wk of iFGFR1 activation, multibud, type II le-
sions appeared along the primary duct. These were the pre-
dominant morphology observed in the mammary gland of
AP20187 treated transgenic mice (Fig. 3 A, type II). Type II
lesions contained multiple cell layers and had collapsed lu-
mens (as determined by ZO-1 localization) (Fig. 3 A). Cells
at the periphery of type II lesions still remained organized
around the basement membrane (as determined by anti-lami-
nin immunofluorescent staining). Similar to type I lateral
buds, these lesions remained closely associated with primary
ducts, expressed PR, and were not highly invasive into the
surrounding stroma (Fig. 3 A, type II; unpublished data).
Type III lesions were first observed after 
 
 
 
4 wk of
AP20187 treatment and appeared as multifocal lesions along
ducts (Fig. 3 A, type III, whole mount). Type III lesions ex-
hibited a marked loss of laminin and ZO-1 expression, and
were multicellular, invasive, and highly vascularized (Fig. 3
A, type III, H&E and immunofluorescence). These lesions
were often associated with a surrounding leukocyte infiltra-
tion and reactive stroma (Fig. 3 A, type III, H&E). Interest-
ingly, analysis of the more invasive type III lesions by FACS
suggests that these lesions were predominantly diploid (un-
published data). Thus, type III lesions have some character-
istics similar to intraepithelial neoplasia and thus may repre-
sent a preneoplasiac growth.
 
iFGFR1 dimerization induces proliferation and 
activation of signaling pathways in vivo
 
Dimerization-induced phosphorylation of the iFGFR1 pro-
tein and downstream signaling pathways were analyzed by
 
Western blotting and immunofluorescence in transgenic
mice 24 h after the completion of a 2-wk treatment with
AP20187. Protein extracts isolated from AP20187-treated
and -untreated transgenic littermates showed increased
iFGFR1, Akt, and MAPK phosphorylation only in treated
mice (Fig. 4, A and B). In transgenic mice treated for
16 d, immunolocalization of the phosphorylated (Thr202/
Tyr204) MAPK correlated with the lateral bud lesions (Fig.
4, C and D). These results suggest that AP20187 treatment
induced the phosphorylation and activation of the iFGFR
signaling cascade in transgenic mice similar to that observed
in NIH3T3 and HC11 cells.
The percentage of cells in S phase was quantitated in lat-
eral buds as determined by BrdU incorporation to assess
whether AP20187-induced lateral buds were hyperprolifera-
tive in response to activated iFGFR signaling. BrdU was ad-
ministered to AP20187-treated and untreated transgenic
mice 2 h before sacrifice and localized in the mammary epi-
thelium using a FITC-conjugated anti-BrdU antibody (Fig.
4, E and F). In untreated transgenic mice, 0.9% (
 
 
 
 0.2
SEM) of mammary epithelial cells were positive for BrdU.
However, after 28 d of AP20187 treatment, BrdU was de-
tected in 9.5% (
 
 
 
 1.4 SEM) of mammary epithelial cells.
The number of BrdU-positive cells found in lateral buds and
ductal cells was 8.5% (
 
 
 
 1.6 SEM) and 11.7% (
 
 
 
 1.9
SEM), respectively. No significant differences were observed
in apoptosis between treated and untreated transgenic mice
as measured by TdT-mediated dUTP-biotin nick end label-
ing (TUNEL) staining (unpublished data). These results
suggest that activation of the iFGFR1 kinase induces prolif-
eration not only in regions of phenotypic lateral buds, but
also within the ductal epithelium.
Transgenic mice were treated for 3 d with AP20187, fol-
lowed by 120 h of drug withdrawal to assess the reversibility of
the system. The half-life of AP20187 in the bloodstream has
been determined previously to be 
 
 
 
7 h (Tim Clackson,
ARIAD Pharmaceuticals, personal communication). Both the
increase in MAPK phosphorylation and proliferation in the
Figure 3. Histology of iFGFR1-induced lesions 
in the mammary gland. Three histologically distinct 
lesions are observed in AP20187-treated trans-
genic mouse mammary glands. (A) Panel shows 
gross mammary gland morphology by whole 
mounts (10  magnification), cellular detail by 
H&E stain (20 and 40 ), and cellular polarity by 
immunofluorescence analysis (100 ) with anti-
ZO-1 (Texas red) and anti-laminin (FITC). Type I 
lesions initially appeared by day 3 of treatment, 
and are characterized by the punctate appearance 
of lateral buds lining the ductal epithelium (Type I, 
whole mount). Type I lateral buds contain a single 
layer of polarized mammary epithelial cells with 
large distinct lumens (Type I, H&E and ZO-1/
Laminin). Type II lesions appear starting at week 2 
of AP20187 treatment, and are distinguished by 
uniform multicellular epithelium with small 
collapsed lumens (Type II). Type III lesions are 
multicellular, invasive, well vascularized, and 
have lost ZO-1 and laminin expression (Type III). 
Bars, 5  m.  
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mammary epithelium were not reversible after injections of
AP20187 were stopped for 120 h before tissue biopsy (Fig. 4,
G and H). Similar results were obtained when mice were
treated with AP20187 for 6 wk followed by a withdrawal inter-
val of 2 wk before to tissue biopsy (unpublished data).
 
iFGFR1 activation alters mammary 
epithelial cell polarity
 
Mammary epithelial cells undergo an intrinsic apoptotic re-
sponse upon detachment from the basement membrane, a pro-
cess termed anoikis. Confocal microscopy was utilized to deter-
mine if the iFGFR1-induced lesions contain cellular layers
detached from the basement membrane. Thick frozen sections
of mammary glands isolated from AP20187-treated transgenic
mice were stained with anti–E-cadherin (Texas red) and lami-
nin (FITC) antibodies (Fig. 4, I and J). Wild-type midpreg-
nant mice were used as a control to contrast alveolar buds
with iFGFR1-induced lesions. Confocal microscopic analysis
showed that the mammary epithelium forms a single layer of
cells contacting both the laminin-rich basement membrane
(Fig. 4 I, arrowhead) and lumenal space (Fig. 4 I, asterisk) in
wild-type midpregnant mice. Additionally, E-cadherin localiza-
tion was observed only on lateral sides of epithelial cells, at sites
of cell-to-cell contact, and not at the apical or basal membranes
(Fig. 4 I, arrow). Transgenic mice treated with AP20187
formed multicellular layers with inner (lumenal) layers detached
from the basement membrane (Fig. 4 J, arrow). Additionally,
E-cadherin staining was observed on the entire periphery of epi-
thelial cells, suggesting cell-to-cell contact was no longer re-
stricted to lateral membranes (Fig. 4 J, arrow). The loss of at-
tachment to the basement membrane and peripheral contacts
with neighboring cells suggests that iFGFR1-induced lesions
are no longer responsive to polarity signals, including anoikis.
This is consistent with iFGFR1 signaling inhibiting apoptosis
and inducing proliferation in the mammary epithelium
 
.
 
iFGFR1-induced lesions have invasive characteristics
 
The presence of myoepithelial cells, extracellular matrix
(ECM) and the vascular network were analyzed in AP20187-
treated transgenic mice to assess the invasive characteristics
of iFGFR1-induced lesions. The matrix metalloproteinases
(MMPs) are a family of related Zn
 
  
 
 interacting proteases
that are increasingly implicated in tumorigenesis (Benaud et
al., 1998; John and Tuszynski, 2001). Analysis of MMP ac-
tivity in conditioned media from iFGFR1-expressing mam-
mary epithelial cells was used to determine if MMPs are
regulated through iFGFR1 signaling. Using gelatin zymogra-
 
Anti-BrdU immunofluorescence from wild-type (E) and transgenic (F) 
mice treated with AP2087 for 4 wk and pulsed with BrdU for 2 h. 
To determine reversibility, iFGFR mice were treated for 3 d with 
AP20187, and treatment was stopped 120 h before tissue biopsy. 
Phosphorylated MAPK (Texas red) and proliferation (anti–BrdU-FITC) 
were detected in the AP20187-treated (G) and AP20187-withdrawal 
biopsy (H). Confocal microscopic and immunofluorescence analysis 
of midpregnant wild-type (I) and 2-wk AP20187-treated transgenic (J) 
mammary glands using anti–E-cadherin (Texas red, arrows) and anti-
laminin (FITC, arrowhead) antibodies. AP20187-treated transgenic 
mice show multi-cell layering (distance between arrowhead and 
arrow), collapsed lumens (asterisks), and peripheral localization 
of E-cadherin. Bars, 5 
 
 
 
m.
 
Figure 4.
 
AP20187 treatment of transgenic mice induces 
proliferation and altered cell polarity in the mammary gland.
 
 (A) 
Immunoprecipitation with anti-HA epitope antibodies and Western 
analysis using anti–phospho-tyrosine and HA-epitope antibodies of 
extracts from transgenic mice treated with AP20187 (
 
 
 
) or diluent 
(
 
 
 
) for 2 wk. iFGFR1 shows increased phosphorylation levels in 
AP20187-treated transgenic mice. (B) Western blot analysis showing 
increased phosphorylation levels of MAPK and Akt in AP20187-treated 
transgenic mice (MMTV-iFGFR1) over wild-type mice treated with 
diluent (wt). The positive control was iFGFR1-transduced NIH3T3 
cells (NIH3T3-iFGFR1) treated with AP20187. Immunofluorescence 
analysis with anti–phospho-MAPK antibody (Texas red) and DAPI in 
wild-type (C) and transgenic (D) mice treated with AP20187 for 2 wk.  
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phy, medium from serum-starved iFGFR1-expressing HC11
mammary epithelial cells treated with AP20187 showed in-
creased MMP activity over solvent treated cells (Fig. 5 A).
Gelatinase activity was inhibited when the chelating reagent
EDTA was added to the incubation buffer (Fig. 5 A). Addi-
tionally, increased gel migration of MMP-9 was observed af-
ter pretreatment of the protein extracts with p-aminophe-
nylmercuric acetate (APMA), an inducer of autocatalytic
cleavage of proMMPs (Fig. 5 A). These data demonstrate
that iFGFR1 activation in mammary epithelial cells can in-
duce MMP-2 and MMP-9 activity.
The presence of the myoepithelial cell barrier in mammary
glands from AP20187-treated mice was analyzed by confocal
microscopy using antibodies against the specific myoepithelial
cell markers keratin-14 (K-14) and 
 
 
 
-actin. In untreated wild-
type mice, a continuous K-14–positive cell layer was observed
between the luminal epithelium and stromal cell compartments
(Fig. 5 B). However, fewer K-14–positive myoepithelial cells
surrounding lateral buds were observed in transgenic mice after
2 wk of AP20187 treatment. Additionally, primary ducts asso-
ciated with the lateral buds displayed noncontiguous and
patchy K-14 staining along the duct (Fig. 5 C). Similar results
were obtained using antibodies against smooth muscle 
 
 
 
-actin
(unpublished data). The absence of myoepthelial cells correlates
with a reduction of proteinaceous ECM surrounding the
iFGFR1 induced lateral buds, as observed by Masson’s tri-
chrome staining (Fig. 5, D and E). However, although collagen
IV (unpublished data) and laminin (Fig. 4 H) staining was still
observed in the basal lamina surrounding lateral buds, their ex-
pression appeared more disorganized than in untreated mice.
These data suggest that iFGFR1 activation can initiate the reor-
ganization and breakdown of ECM surrounding the lateral
buds.
Proliferation of the epithelium in the mammary gland re-
quires concomitant changes not only in the underlying stroma,
but also in the vascular network supporting the new growth.
The vascular network surrounding iFGFR1-induced lateral
buds was observed in situ using confocal microscopy and
FITC-lectin visualization of blood vessels. To visualize blood
vessels, 2-wk AP20187-treated transgenic mice were injected
into the left ventricle with FITC-
 
Lycopersicon esculentum
 
 lectin.
FITC-lectin–injected mice were perfused with fixative, and
mammary glands were biopsied and frozen in OCT com-
pound. Mammary glands were cryosectioned and stained with
Texas red phalloidin to identify the mammary epithelium.
Confocal imaging and software-rendered three-dimensional re-
constitution revealed a highly branched network of blood ves-
sels surrounding iFGFR1-induced lateral buds (Fig. 5, F and
G). Lateral buds were primarily associated with small tortuous
vessels branching off of larger vessels lining the ductal epithe-
lium (Fig. 5, F and G, arrows). These data suggest that sprout-
ing angiogenesis from the existing ductal vascular network may
be initiated indirectly by iFGFR1 signaling in the mammary
epithelium.
 
Discussion
 
Several mouse models of breast cancer have been developed,
but the utility of these models in studying the early events in
Figure 5. iFGFR1 activation can regulate MMPs and induce 
invasive lesions. (A) iFGFR-transduced HC11 cells were serum 
starved for 16 h and treated with AP20187 or diluent in serum-
free media for 24 h. Media was collected, concentrated, and 
loaded in equal volumes on a gelatin zymography gel. Media 
isolated from AP20187-treated cells showed increased levels of 
MMP-9 and MMP-2 activity. APMA treatment of media for 1 h 
before gel loading increased the mobility of MMP-9, demonstrating 
conversion of proMMP-9 to active MMP-9. No APMA induced 
mobility shift was observed with MMP-2, suggesting only active 
MMP-2 was present. EDTA (5 mM) treatment in the incubation 
buffer inhibited MMP activity. (B and C) Indirect immunofluorescence 
analysis using anti-keratin-14 antibodies (Texas red) demonstrates 
that AP20187-treated iFGFR1 mice have reduced myoepithelium 
surrounding lateral buds. (D) Masson’s trichrome stain of 
untreated transgenic mouse mammary gland epithelium showing 
blue stained collagen (arrow) surrounding the duct. (E) AP20187-
treated mouse mammary gland with reduced collagen matrix 
surrounding the duct and lateral buds (arrows). (F and G) Confo-
cal microscopy of the vascular network (FITC-lectin) surrounding 
the mammary epithelium (Texas red phalloidin) from AP20187-
treated mice, showing increased vessel branching (arrows) associated 
with lateral buds. Bars, 5  m. 
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transformation of the mammary gland is limited due to the
inability to regulate oncogenic events. One exception to this
is the use of the tetracycline-inducible system to drive ex-
pression of oncogenes in the mammary epithelium (D’Cruz
et al., 2001). In this paper we describe a novel inducible
mouse model of breast cancer that can be used to study the
early progressive steps of tumorigenesis (Fig. 6 A). The
iFGFR model is the first use of an inducible-dimerization
system of a tyrosine-kinase receptor in transgenic mice.
Activation of iFGFR signaling in the mammary gland re-
sults in several distinct stages of transformation, including
epithelial hyperproliferation (observable 72 h after AP20187
treatment) and stromal invasion (Fig 6 A). Several factors,
including MMP regulation, ECM remodeling, and absence
of a myoepithelial cell barrier, may contribute to the inva-
siveness of these lesions (Fig. 6 B). Myoepithelial cells play a
role in the production and maintenance of the ECM barrier
that surrounds ductal epithelium, and secrete antiangiogenic
factors (Xiao et al., 1999; Nguyen et al., 2000). Loss of
myoepithelium and ECM is associated with invasive charac-
teristics in breast cancer (Batsakis and el-Naggar, 1999; Xiao
et al., 1999). Moreover, the ECM has been implicated in an
active role in the regulation of proliferation, differentiation,
and angiogenesis by regulating growth factor bioavailabil-
ity (Coussens et al., 2000; Silberstein, 2001). Coussens et
al. (2000) have demonstrated that neutrophils expressing
MMP-9 induce angiogenesis by releasing VEGF from the
ECM, thus increasing its availability to endothelial cells
(Coussens et al., 2000). Interestingly, we have observed that
conditioned media isolated from iFGFR1-transduced mam-
mary epithelial cells treated in culture with AP20187 dis-
played an increased MMP-9 and MMP-2 activity. Consis-
tent with these data, reduced ECM and increased vascular
branching surrounding iFGFR-induced lesions was observed
in AP20187-treated transgenic mice. However, it is likely
that the invasive nature of type III lesions may be aug-
mented by infiltration of leukocytes and increased secretion
of MMP-9 (Coussens et al., 2000). Long-term treatment
(3–12 mo) of transgenic mice with AP20187 will be needed
to determine if the localized invasive nature of type III le-
sions are premalignant and can progress to adenocarcinomas
with metastatic potential.
The rapid 4-wk time period from the appearance of initial
type I to the invasive type III lesions suggests that iFGFR1 sig-
naling in mammary epithelium exerts both potent prolifera-
tive and antiapoptotic effects (Fig. 6 A). However, the com-
plex nature of iFGFR1-induced lesions, including the loss of
myoepithelium and increased vascular branching, suggest that
other indirect effects mediated through stromal interactions
also contribute to the invasive characteristics. The conversion
Figure 6. Model for FGFR-induced lateral buds 
and hyperplasia in the mammary gland. (A) 
Acute iFGFR signaling in the mammary epithelium 
induces lateral buds (type I) within 72 h of treatment 
with AP20187. Continuous treatment for 2 wk 
results in multicellular epithelium (type II) that 
can progress into invasive lesions (type III) after 
 4 wk of treatment. (B) Normal mammary 
epithelial cells are polarized (box) with apical 
localization of ZO-1 at tight junctions, and 
lateral localization of E-cadherin. The ECM and 
myoepithelium at the basement membrane can 
regulate the bioavailability of growth factors and 
inhibit angiogenesis. Acute iFGFR activity in the 
mammary epithelium induces proliferation and 
upregulation of ECM proteases resulting in 
epithelial invasion into the stroma and the 
formation of lateral buds. Disruption of the ECM, 
through MMP upregulation ( ), may induce 
vascular branching by increasing the bioavailability 
of endothelial growth factors ( ), thus supporting 
epithelial growth. However, chronic iFGFR 
activation results in disorganized cell polarity 
including peripheral localization of E-cadherin 
and loss of ZO–1 localization at tight junctions. 
Additionally, the loss of anti-angiogenic factors 
associated with the myoepithelium may contribute 
to the invasive characteristics of the iFGFR-
induced lesions. Through these mechanisms, 
FGFR signaling during ductal morphogenesis 
may function in the proliferation and invasion 
of mammary epithelium to establish a ductal 
network, whereas its aberrant regulation may 
play a role in breast cancer. 
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of a single layer ductal epithelium to multicell layers found in
type II and type III lesions suggest that iFGFR kinase activity
inhibited the apoptosis that is normally associated with de-
tachment of lumenal epithelial cells from the basement mem-
brane. In iFGFR1-expressing mice treated with AP20187, no
significant changes in apoptosis were observed by TUNEL
staining when compared with untreated mice (unpublished
data). Levels of apoptosis in the ductal epithelium of mature
virgin mice detected by the TUNEL assay are extremely low
(
 
 
 
0.1%), thus limiting the ability to detect a decrease in ap-
optosis (Humphreys et al., 1996; Rosfjord and Dickson,
1999). Interestingly, recent studies using an MMTV LTR-
driven Tet-regulatable system have shown that after c-myc ac-
tivation, there is an increase in both proliferation and apopto-
sis, reaching levels of 
 
 
 
10% in the ductal epithelial cells
(D’Cruz et al., 2001). Increased lateral budding and mam-
mary hyperplasia were also observed in this transgenic model,
but required a long latency during which other stochastic
events, such as Kras2 activation may occur (D’Cruz et al.,
2001). In contrast, iFGFR signaling can directly activate both
proliferation and survival signals within mammary epithelium
to rapidly induce hyperplastic lesions. Moreover, Muth-
uswamy et al. (1999, 2001), using the same inducible dimer-
ization system, demonstrated that activation of ErbB2 but not
ErbB1 in human mammary epithelial MCF10A cells resulted
in similar changes in proliferation and a loss of cell polarity
demonstrating that highly homologous receptor tyrosine ki-
nases can induce differential effects (Muthuswamy et al.,
1999, 2001). The FGF and EGF growth factor receptor fami-
lies share several downstream signaling factors that may ex-
plain the similarity in the iFGFR1- and ErbB2-induced ef-
fects on mammary epithelial cells.
During branching morphogenesis of the 
 
Drosophila
 
 trachea
and mouse lung, signaling between the epithelium and mes-
enchyme is essential in ductal bifurcation, and FGF ligands
and FGFRs have been implicated as critical factors in this pro-
cess (Metzger and Krasnow, 1999; Sekine et al., 1999). The
effects of iFGFR signaling described in this study, and the
pattern of FGF ligand and FGFR expression during ductal
morphogenesis, are consistent with a possible role for this
growth factor family in initiating branching in the mammary
gland (Fig. 6 B). In this study, iFGFR1 kinase activation elic-
ited direct effects on mammary epithelium including regula-
tion of proliferation, apoptosis, and MMP secretion. Ad-
ditional indirect effects, including ECM remodeling and
vascular branching, may function in restructuring the stroma
to provide support for the developing ductal network (Fig. 6
B). Factors initiating branching morphogenesis and lateral
budding should induce similar effects during mammary gland
development. Therefore, it is likely that coordinated FGF sig-
naling during ductal morphogenesis contributes to this devel-
opmental process. Conditional FGFR knockouts will be
important to further substantiate the importance of FGF
function during mammary gland development.
Because transgene expression levels may contribute to
AP20187-independent dimerization of the iFGFR con-
structs, the line used in these studies (4775) had the lowest
levels of protein expression, as detected by Western blot
analysis, and required RT-PCR analysis for mRNA detec-
tion (unpublished data). However, all expressing lines dem-
onstrated AP20187-independent tumorigenesis in parous
mice appearing 6–12 mo after parturition (unpublished
data). It is unlikely that integration effects contribute to this
phenotype, as all lines exhibit both normal mammary gland
morphology in untreated virgin transgenic mice, and tumors
after breeding. It is more likely that during pregnancy and
lactation, transgene expression is upregulated to levels that
favor AP20187-independent activation, resulting in preneo-
plastic lesions and leading to tumorigenesis. This is consis-
tent with the appearance of multifocal intraepithelial neo-
plastic lesions in the mammary glands of untreated parous
mice and the long latency for tumor development (unpub-
lished data). However, we cannot rule out other initiating
factors contributed by pregnancy, lactation, or involution
that may cooperate with iFGFR1 signaling to induce tumor-
igenesis. The use of the MMTV-LTR promoter to drive ex-
pression of the transgene may also contribute to the lack of
reversibility of the lesions through the initiation of an auto-
regulatory loop established upon activation of iFGFR signal-
ing. This is consistent with the observed increase in trans-
gene expression after only 3 d of AP20187 treatment as
detected by Western blot analyses (unpublished data).
Transgenic mice containing iFGFR1 regulated by a tetracy-
cline dependent promoter crossed with mice containing the
reverse tetracycline-dependent transcriptional activator un-
der the control of the MMTV promoter (D’Cruz et al.,
2001), may provide an improved model to regulate both ex-
pression levels of iFGFR1 using doxycycline and iFGFR1
activity using AP20187 resulting in a reversible system in
which to study tumor progression. However, the iFGFR
constructs described in our study have been shown to elicit
reversible effects when expressed downstream of different
promoters in transgenic and tumor cell transplantation
models (unpublished data).
The iFGFR1 transgenic mice provide a mouse model for
the analysis of progression from early hyperproliferative to
invasive lesions in the mammary gland. These mice will be
useful in defining the steps necessary for transformation.
However, these data must be interpreted with the caveat that
the iFGFR transgene contains several differences from the
endogenous FGFR1 that may alter its activation kinetics and
cellular localization. The iFGFR constructs contain only the
intracellular domain of the FGFR and eliminate regulatory
elements found in the extracellular and transmembrane do-
mains (Rousseau et al., 1996; Burke et al., 1998; Wang et
al., 1999). The extracellular domain of the endogenous re-
ceptor confers affinity for ligand and heparin-sulfate pro-
teoglycans that regulate signal intensity, duration, and affect
cellular response. The iFGFR constructs contain a Src myri-
stylation sequence to anchor the receptor to the plasma
membrane. Thus, it is likely that this may influence the lo-
calization of the iFGFR, and also, potentially, the duration
and nature of iFGFR signaling. The examination of signal-
ing molecules that are activated by differentially localized
constructs should reveal whether basolateral versus nonlocal-
ized expression affect the duration and specificity of RTK-
induced signaling pathways. Therefore, further comparison
between iFGFR and FGFR signaling will be required to as-
sess the capacity of the AP20187/FKBPv system to com-
pletely recapitulate the endogenous signaling pathways. 
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Materials and methods
 
Plasmids and cell culture
 
The FGFR1 intracellular kinase domain was cloned by PCR amplification
of the mouse FGFR1 cDNA plasmid pMo/FR1/IRES, a gift from David Or-
nitz (Washington University, St. Louis, MO) using the following primers:
forward 5
 
 
 
-ATTATAGTCGACATGAAGAGCGGCACCAAGAAGAGC-3
 
 
 
and reverse 5
 
 
 
-CTACTTGTCGACGCGCCGTTTGAGTCCACTGTTGG-3
 
 
 
.
The FGFR1 kinase domain was sequenced and subcloned into pSH1/MF
 
v
 
-
F
 
vls
 
-E plasmid providing an NH
 
2
 
-terminal myristylation sequence, two tan-
dem FKBPv domains (F
 
v
 
-F
 
vls
 
), and hemagglutinin epitope sequence (Fan et
al., 1999). The entire iFGFR1 coding region, including the NH
 
2
 
-terminal
myristylation and hemagglutinin epitope sequences, was subcloned into
pMMP, for retroviral transduction experiments (Riviere et al., 1995). For
generating transgenic mice, the iFGFR1 coding sequence was cloned into
the MMTV-KCR transgene cassette, pMKBPA, a gift from Steven Chua and
Franco DeMayo (Baylor College of Medicine, Houston, TX). NIH3T3 cells
were grown in growth media containing DME (GIBCO BRL), 10% bovine
calf serum (JRH), and 50  g ml
 1 gentamicin (Sigma-Aldrich). HC11 cells
were grown in growth media containing RPMI 1640 medium (RPMI) (JRH)
supplemented with 10% fetal bovine serum, 10 ng/ml
 1 EGF (Life Technol-
ogies), 5  g ml
 1 insulin (Sigma-Aldrich), and 50  g ml
 1 gentamicin. Se-
rum starvation media for NIH3T3 and HC11 cells contained only DME or
RPMI, respectively, supplemented with either 30 pM AP20187 (Ariad
Pharmaceuticals) in ethanol or an equal volume of ethanol-diluent alone
as control. The 293T cell growth media contained DME, 10% fetal bovine
serum (Summit), and 50  g ml
 1 gentamicin. For cell transduction, retrovi-
ruses were packaged by cotransfecting pMMP-iFGFR1 or pMMP-FKBPv
plasmids with pCLEco (Imgenex) into 293T cells using FuGene (Roche) fol-
lowing the manufacturer’s protrocol. 48 h after transfection, retrovirus-
containing 293T media was supplemented with 10  g ml
 1 polybrene
(Sigma-Aldrich), syringe filtered using a 0.4- m filter unit (Millipore) and 5
ml were added to 100-mm plates of HC11 or NIH3T3 target cells. The tar-
get cells with retroviral media were spun in a Marathon centrifuge at 1,800
rpm (500 g) for 30 min with a 1/3 rotation of the plate every 10 min to per-
mit equal distribution of media over the plate.
Survival and proliferation assay
For cell survival assays, the pSH1-iFGFR1 construct was cotransfected with
pBKneo into NIH3T3 cells using Fugene. Stable cells were selected by sup-
plementing growth media with 200  g of active G418 ml
 1 for 3 wk.
Pooled NIH3T3 cells were placed in serum-free DME media for 72 h with
daily media changes for morphological analysis. Images were captured us-
ing a Sony CCD-DXC-151A camera. Caspase-3 activity was measured by
cleavage of the fluorogenic substrate Ac-DEVD-AMC (PharMingen).
Briefly, iFGFR1 and FKBPv-transduced NIH3T3 cells were treated with
AP20187 or ethanol diluent in serum-free media for 24 h, followed by cell
lysis and incubation with the fluorogenic peptide according to the manu-
facturer’s protocol. Cell proliferation was measured, following the manu-
facturer’s protocol, by propidium iodide (Roche) staining of AP20187 or
ethanol diluent–treated cells in serum-free media for 48 h. DNA content
was measured by FACS. For in vivo proliferation, a BrdU label retention
assay was performed as previously described by Seagroves et al. (1998).
Assays were performed in triplicate or quadruplicate and repeated at least
two times. BrdU quantitation was performed by counting positive cells
from at least five 40  images from two or more mice.
Western blots and zymography
The following antibodies were used for Western blot analysis: phospho-
MAPK; phospho-Akt and Akt (Cell Signaling); PY20 (BD Transduction Lab-
oratories); FRS2 (Santa Cruz Biotechnology); and HA-epitope (Santa Cruz
Biotechnology). Protein extracts from cultured cells were isolated with Tri-
ton X-100 extraction buffer (150 mM NaCl, 1% Triton X-100, 1  g ml
 1
aprotinin, 1  g ml
 1 benzeamidine, 1  g ml
 1 antipain, 10  g ml
 1 soy-
bean trypsin inhibitor, 0.25  g ml
 1 leupeptin, 100  M PMSF, 100 uM
NaVanadate, 1 mM NaF) and passed through a 26-G syringe five times fol-
lowed by incubation on ice for 45 min. Protein extracts were quantitated
by Bradford assay (Bio-Rad), and 80  g protein was resolved by SDS-PAGE
and transferred onto PVDF membranes (Millipore). Western blot analyses
were followed as previously described (Seagroves et al., 1998). Chemilu-
minsecence was developed following manufacturer’s protocol (Pierce
Chemical Co.). For zymography, 1.5 ml media from AP20187 or ethanol
diluent–treated HC11 cells in serum-free media for 16 h was concentrated
with YM-10MW Centricon membranes following the manufacturer’s pro-
tocol (Millipore), loaded in equal volumes on gelatin zymography gels,
and analyzed as described by Talhouk et al. (1991).
Indirect immunofluorescence and histology
The following primary antibodies were used for indirect immunofluores-
cent detection of specific antigens: rabbit polyclonals were anti–keratin-14
(Convance Research Products); anti-laminin (Dako); and anti–phospho-
MAPK (Cell Signaling). Rat monoclonals were anti–E-cadherin (Zymed)
and anti–ZO-1 (Chemicon), and mouse monoclonals were anti–HA-
epitope (Convance Research Products) and anti-BrdU (Becton Dickinson).
Secondary antibodies were: anti–mouse Texas red; Texas red anti–rat; FITC
anti–rabbit; and Texas red anti–rabbit (Molecular Probes). Tissue was pro-
cessed and stained as previously described (Seagroves et al., 1998). For
confocal microscopic analysis of frozen sections, tissue was fixed in 4%
PFA/PBS for 2 h and frozen in OCT. Frozen sections were cut (50  m) and
stained overnight with primary antibody in 3%BSA/PBS. Sections were
washed in PBS for 10 min and stained with secondary antibodies for 5 h.
Sections were then washed for 30 min, mounted with Vectashield, and an-
alyzed using a Zeiss 510 laser scanning confocal microscope. Whole
mounts were prepared as previously described (Williams and Daniel,
1983), and images were captured using Olympus dissecting microscope
and Sony video camera (#DXC-151A). H&E sections were prepared as pre-
viously described (Seagroves et al., 1998). Masson’s trichrome staining
was performed with Accustain Trichrome Stain following the manufac-
turer’s protocol (Sigma-Aldrich).
FITC-lectin perfusion
Mice were implanted with Alzet minipumps (Alzet) containing 100  l of
0.5 mg ml
 1 AP20187, delivering 0.25  l h
 1 for 2 wk. Mice were anes-
thetized after 2 wk with Avertin followed by left ventricular injection of Ly-
copersicon esculentum FITC-lectin (Vector). After 5 min, 5 ml of 1% para-
formaldehyde/0.5% gluteraldehyde/PBS was perfused followed by 5 ml of
PBS. Tissue was then dissected and frozen in OCT. For confocal micros-
copy, thick 50- m sections of OCT embedded tissue were cut and post-
fixed in 4% PFA/PBS for 10 min at room temperature. Sections were then
permeablized with 1% Triton X-100 in PBS for 10 min at room tempera-
ture, washed in PBS for 5 min, and stained for 5 h with phalloidin-
Alexa594 (Molecular Probes). Sections were washed for 20 min in PBS,
mounted with Vectashield, and imaged.
Online supplemental material
Supplemental videos are available at http://www.jcb.org/cgi/content/full/
200107119/DC1. Video 1 shows a midpregnant mouse mammary gland
consisting of a single cell layer of polarized mammary epithelium. Three-
dimensional rotation of the midpregnant mammary gland demonstrates the
single-cell epithelial layer between the basement membrane and lumen.
Video 2 represents iFGFR1-induced lesions containing multicell-layered
mammary epithelium with altered cell polarity. Confocal imaging through
the iFGFR1-induced lesion demonstrates the multiple cell layers, reduced
lumen size, and peripheral staining of E-cadherin observed throughout these
lesions. Videos 3 and 4 show increased vascular branching surrounding
iFGFR1-induced lateral buds. Confocal immunofluorescence and three-
dimensional imaging of the vascular network shows the close proximity and
branching of blood vessels surrounding iFGFR1-induced lateral buds.
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